Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough

Respiratory Research
•    Research
• Open Access

• Li Long†,
• Hongmei Yao†,
• Jing Tian†,
• Wei Luo,
• Xinxin Yu,
• Fang Yi,
• Qiaoli Chen,
• Jiaxing Xie,
• Nanshan Zhong†,
• Kian Fan Chung† and
• Kefang Lai†Email author

†Contributed equally

Respiratory Research201920:112

https://doi.org/10.1186/s12931-019-1077-z

Abstract

Background

The differential sensitivity of cough to antitussive therapies implies the existence of heterogeneity in cough hypersensitivity, but how such heterogeneity is expressed across individual patients is poorly understood. We investigated the phenotypes of cough hypersensitivity by examining transient receptor potential ankyrin 1 (TRPA1)- and transient receptor potential vanilloid 1 (TRPV1)-mediated cough sensitivity in patients with chronic refractory cough.

Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis

Clinical and Translational Allergy 
•   Review
• Open Access

• Ralph Mösges†,
• Antonio Valero Santiago†,
• Silke Allekotte,
• Nilufar Jahed,
• Anatoli Astvatsatourov,
• Angelika Sager and
• Jaime Sánchez-LópezEmail authorView ORCID ID profile

†Contributed equally

Clinical and Translational Allergy20199:29

https://doi.org/10.1186/s13601-019-0268-5

Abstract

Background

Double-blind, placebo-controlled trials (DBPCTs) have confirmed the efficacy of allergen-specific immunotherapy (AIT) with depigmented-polymerized allergen extracts (DPAEs). This systematic review evaluates the efficacy of AIT using different allergens in different severity stages of rhinoconjunctivitis with or without asthma in the pollen studies and asthma and rhinitis in the house dust mite studies in comparison to placebo.

A specific synbiotic-containing amino acid-based formula restores gut microbiota in non-IgE mediated cow’s milk allergic infants: a randomized controlled trial

Clinical and Translational Allergy
• Research
• Open Access

• Harm WopereisView ORCID ID profile,
• Marleen T. J. van Ampting,
• Aysun Cetinyurek-Yavuz,
• Rob Slump,
• David C. A. Candy,
• Assad M. Butt,
• Diego G. Peroni,
• Yvan Vandenplas,
• Adam T. Fox,
• Neil Shah,
• Guus Roeselers,
• Lucien F. Harthoorn,
• Louise J. Michaelis,
• Jan KnolEmail author,
• Christina E. West and
• the ASSIGN study group

Clinical and Translational Allergy20199:27

https://doi.org/10.1186/s13601-019-0267-6

Abstract

Background

Altered gut microbiota is implicated in cow’s milk allergy (CMA) and differs markedly from healthy, breastfed infants. Infants who suffer from severe CMA often rely on cow’s milk protein avoidance and, when breastfeeding is not possible, on specialised infant formulas such as amino-acid based formulas (AAF). Herein, we report the effects of an AAF including specific synbiotics on oral and gastrointestinal microbiota of infants with non-IgE mediated CMA with reference to healthy, breastfed infants.

Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials

Respiratory Research
•  Research
• Open Access

• Xiao-feng Xiong,
• Min Zhu,
• Hong-xia Wu,
• Li-li Fan and
• De-yun ChengEmail author

Respiratory Research201920:108

https://doi.org/10.1186/s12931-019-1065-3

Abstract

Background

Several recent clinical trials have assessed the effects of dupilumab in uncontrolled asthma, but reached no definite conclusion. We therefore conducted this meta-analysis to evaluate the overall efficacy and safety of dupilumab for the treatment of uncontrolled asthma.

Read the latest research in Allergy and Immunology

Dear DR

We want to alert you to a selection of featured journals from our open access Allergy and Immunology portfolio. Choose the journal that fits your research and stay up to date with the latest research - browse our portfolio below!

Identification of immunodominant IgE binding epitopes of Der p 24, a major allergen of Dermatophagoides pteronyssinus

Clinical and Translational Allergy

• Ze-Lang Cai†,
• Jia-Jie Chen†,
• Zhen Zhang,
• Yi-Bo Hou,
• Yong-shen He,
• Jin-Lyu SunEmail author and
• Kunmei JiEmail authorView ORCID ID profile

†Contributed equally

Clinical and Translational Allergy20199:28

Abstract

Background

The identification of house dust mite (HDM) allergens and epitopes is important for allergy diagnosis and treatment. We sought to identify the Dermatophagoides pteronyssinus group 24 allergen (Der p 24) and to identify its immunodominant IgE epitope(s).

Immunosuppressive therapy with rituximab in common variable immunodeficiency

• Open Access

• Antonio Pecoraro,
• Ludovica Crescenzi,
• Maria Rosaria Galdiero,
• Giancarlo Marone,
• Felice Rivellese,
• Francesca Wanda Rossi,
• Amato de Paulis,
• Arturo Genovese and
• Giuseppe SpadaroEmail authorView ORCID ID profile

Clinical and Molecular Allergy201917:9

Abstract

Common variable immunodeficiency (CVID) is the most frequent symptomatic primary antibody deficiency in adulthood and is characterized by the marked reduction of IgG and IgA serum levels. Thanks to the successful use of polyvalent immunoglobulin replacement therapy to treat and prevent recurrent infections, non-infectious complications, including autoimmunity, polyclonal lymphoproliferation and malignancies, have progressively become the major cause of morbidity and mortality in CVID patients. The management of these complications is particularly challenging, often requiring multiple lines of immunosuppressive treatments. Over the last 5–10 years, the anti-CD20 monoclonal antibody (i.e., rituximab) has been increasingly used for the treatment of both autoimmune and non-malignant lymphoproliferative manifestations associated with CVID.

Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates

Respiratory Research  
• Research
• Open Access

• Cédric VonarburgEmail authorView ORCID ID profile,
• Marius Loetscher,
• Martin O. Spycher,
• Alain Kropf,
• Marlies Illi,
• Sharon Salmon,
• Sean Roberts,
• Karin Steinfuehrer,
• Ian Campbell,
• Sandra Koernig,
• Joseph Bain,
• Monika Edler,
• Ulrich Baumann,
• Sylvia Miescher,
• Dennis W. Metzger,
• Alexander Schaub,
• Fabian Käsermann and
• Adrian W. Zuercher

Respiratory Research201920:99

https://doi.org/10.1186/s12931-019-1057-3

Abstract

Background

Recurrent and persistent infections are known to affect airways of patients with Primary Immunodeficiency despite appropriate replacement immunoglobulin serum levels. Interestingly, patients with Chronic Obstructive Pulmonary Disease or with non-CF bronchiectasis also show similar susceptibility to such infections. This may be due to the limited availability of immunoglobulins from the systemic circulation in the conductive airways, resulting in local immunodeficiency. Topical application of nebulized plasma-derived immunoglobulins may represent a means to address this deficiency. In this study, we assessed the feasibility of nebulizing plasma-derived immunoglobulins and delivering them into the airways of rats and non-human primates.